Novo Nordisk Pharmatech A/S Annual Report 2016

Wednesday 22.02.2017

Novo Nordisk Pharmatech A/S Annual Report 2016

Our Annual Report reviews the performance of Novo Nordisk Pharmatech A/S in 2016.

Download the full performance summary

Annual Report 2016 Annual Report 2016

Performance 2016

Novo Nordisk Pharmatech A/S (abbreviated as NNPR) is a fully owned subsidary of Novo Nordisk A/S. Novo Nrodisk is the biggest customer buying Silica gel, Enzymes, Analytical Columns and Micro-analysis services. NNPR are manufacturing and selling active pharmaceutical ingredients (API) and excipients to the pharmaceutical and biopharmaceutical industry comprising of quaternary amines and Human Insulin. The majority of these products are exported throughout the world, with the US as the largest market.

Development in 2016

NNPR's revenue in 2016 was DKK 669,077k which was 32 % higher than in 2015. The underlying resaons for the increase were:
  • Strong sales development on exported products with a growth of 19 % derived from a combination of increased volume price and exchange rate.
  • Increase in sales to Novo Nordisk of 51 % compared to 2015. 2015 included a one-off reduction in IPC costs due to the new valuation method of valuing inventory.

Knowledge capital of NNPR

It is the foundation of NNPR to be a quality supplier of high value products to the pharmaceutical and the biopharmaceutical industry. The knowledge capital of NNPR is within 6 main areas: silica gel technology, purification of proteins, micro-analysis, analytical columns, cGMP production of quaternary amines and insulin for technical use. NNPR is a competence centre for the use of silica gels for chromatographical purification in Novo Nordisk. The technological knowledge is secured by interaction with users in production, process support and R&D departments in Novo Nordisk. Furthermore improvements are implemented to the mechanical and chemical lifetime of the product, often in close cooperation with the suppliers. This work forms the basis for continuous improvements of the products in NNPR and contributes to reducing costs in Novo Nordisk for purification of products and this is expected to continue. NNPR is building up knowledge within the application of insulin as excipients in the production of biopharmaceutical products. This will support and develop that part of NNPR’s business.

Corporate Social Responsibility

NNPR strives to conduct its activities in a financially, environmentally and socially responsible way. The Corporate social responsibility equals the concept of the Triple Bottom Line. The environmental and social activities are described below under “Health, safety and environment”. For NNPR, climate change is part of our approach to environmental management and encompasses ongoing focus on saving energy and reduction of emissions of organic solvents to the atmosphere. With respect to human rights, NNPR defines the company’s focus as its own employees and their rights and well-being. Therefore, beside ensuring legal compliance with worker’s rights, discrimination and the right to organize at all times, our activities towards human rights include general safety and prevention of accidents, prevention of stress and work related illnesses as wells as ensuring general good health among our employees. NNPR supports the fight against bribery in international business, as bribery undermines sustainable development and the rule of law. We are committed to complying with all local law and regulations, including the United States’ Foreign Corrupt Practices Act and the United Kingdom’s Bribery Act.